Abstract
Adenocarcinoma of the pancreas is the fourth leading cause of cancer death in the United States. Because of the poor therapeutic responsiveness of pancreatic cancer to surgery, chemotherapy, and radiation therapy, survival beyond five years is rare with median survival less than six months. K-ras mutations have been identified in up to 95% of pancreatic cancers, implying their critical role in the molecular pathogenesis. Ras overexpression leads to increased production of reactive oxygen species (ROS) through activation of the NADPH oxidase system resulting in downstream propagation of mitogenic signaling leading to cell growth and tumor progression. The superoxide dismutases (SOD) convert O2 .- into H2O2. Extracellular SOD (ECSOD) is the only isoform of SOD that is expressed extracellularly, manganese-containing superoxide dismutase (MnSOD) is localized in the mitochondria, and copper- and zinc-containing superoxide dismutase (CuZnSOD) in the cytoplasm. The catalases and peroxidases convert H2O2 into water. Catalase is located in peroxisomes and cytoplasm and peroxidases are in many subcellular compartments. Antioxidant enzymes that scavenge specific ROS have inhibited the in vitro and in vivo growth of pancreatic cancer. Additionally, food-derived polyphenols, which may act by scavenging reactive oxygen species, can also inhibit pancreatic cancer growth. This review will concentrate on the sophisticated antioxidant defense system, which may shed insight into the etiology, diagnosis, and treatment of pancreatic cancer.
Keywords: reactive oxygen species (ROS), SOD protein, NADPH oxidase (NOX), GPx isoenzymes, PhGPx-immunoreactive protein
Current Cancer Therapy Reviews
Title: The Role of Antioxidant Enzymes in the Growth of Pancreatic Carcinoma
Volume: 3 Issue: 1
Author(s): Nazee Jabbari and Joseph J. Cullen
Affiliation:
Keywords: reactive oxygen species (ROS), SOD protein, NADPH oxidase (NOX), GPx isoenzymes, PhGPx-immunoreactive protein
Abstract: Adenocarcinoma of the pancreas is the fourth leading cause of cancer death in the United States. Because of the poor therapeutic responsiveness of pancreatic cancer to surgery, chemotherapy, and radiation therapy, survival beyond five years is rare with median survival less than six months. K-ras mutations have been identified in up to 95% of pancreatic cancers, implying their critical role in the molecular pathogenesis. Ras overexpression leads to increased production of reactive oxygen species (ROS) through activation of the NADPH oxidase system resulting in downstream propagation of mitogenic signaling leading to cell growth and tumor progression. The superoxide dismutases (SOD) convert O2 .- into H2O2. Extracellular SOD (ECSOD) is the only isoform of SOD that is expressed extracellularly, manganese-containing superoxide dismutase (MnSOD) is localized in the mitochondria, and copper- and zinc-containing superoxide dismutase (CuZnSOD) in the cytoplasm. The catalases and peroxidases convert H2O2 into water. Catalase is located in peroxisomes and cytoplasm and peroxidases are in many subcellular compartments. Antioxidant enzymes that scavenge specific ROS have inhibited the in vitro and in vivo growth of pancreatic cancer. Additionally, food-derived polyphenols, which may act by scavenging reactive oxygen species, can also inhibit pancreatic cancer growth. This review will concentrate on the sophisticated antioxidant defense system, which may shed insight into the etiology, diagnosis, and treatment of pancreatic cancer.
Export Options
About this article
Cite this article as:
Jabbari Nazee and Cullen J. Joseph, The Role of Antioxidant Enzymes in the Growth of Pancreatic Carcinoma, Current Cancer Therapy Reviews 2007; 3 (1) . https://dx.doi.org/10.2174/157339407780126610
DOI https://dx.doi.org/10.2174/157339407780126610 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Efficient Colonic Delivery of DsiRNA by Pectin-Coated Polyelectrolyte Complex Nanoparticles: Preparation, Characterization and Improved Gastric Survivability
Current Drug Delivery Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell
Current Pharmaceutical Biotechnology From Body Art to Anticancer Activities: Perspectives on Medicinal Properties of Henna
Current Drug Targets Tandem Multicomponent Reactions Toward the Design and Synthesis of Novel Antibacterial and Cytotoxic Motifs
Current Medicinal Chemistry Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Biomimetic Drug Delivery Systems Oriented by Biological Function in Tumor Targeting
Current Drug Targets Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Dual Modulators of p53 and Cyclin D in ER Alpha Signaling by Albumin Nanovectors Bearing Zinc Chaperones for ER-positive Breast Cancer Therapy
Mini-Reviews in Medicinal Chemistry Design, Optimization and Characterization of Nanostructured Lipid Carriers of Raloxifene Hydrochloride for Transdermal Delivery
Nanoscience & Nanotechnology-Asia Electric cable: cytoskeleton as an electric transmitter for cancer therapy
Current Signal Transduction Therapy Polymeric Systems as Nanodevices for siRNA Delivery
Current Gene Therapy Molecular Aspects of Stromal-Parenchymal Interactions in Malignant Neoplasms
Current Molecular Medicine Advances in Tumor Targeted Liposomes
Current Molecular Medicine Localised Delivery of Therapeutic Agents to CNS Malignancies: Old and New Approaches
Current Pharmaceutical Biotechnology n-3 Polyunsaturated Fatty Acids as Signal Transduction Modulators and Therapeutical Agents in Cancer
Current Signal Transduction Therapy Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design 7-O-aminoalkyl-2,3-dehydrosilibinins: Synthesis and in vitro Anti-cancer Efficacy
Anti-Cancer Agents in Medicinal Chemistry Analysis of Oxaliplatin Resistance in Colorectal Cancer Cells by Combined Proteomics and Phosphoproteomic
Current Proteomics